In a report released on November 6, Brian Abrahams from RBC Capital maintained a Buy rating on BioCryst (BCRX – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $5.47.
According to TipRanks, Abrahams is a 4-star analyst with an average return of 2.9% and a 41.68% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as BioCryst, Ambrx Biopharma, and Biogen.
In addition to RBC Capital, BioCryst also received a Buy from Needham’s Serge Belanger in a report issued on November 6. However, on November 3, Barclays maintained a Hold rating on BioCryst (NASDAQ: BCRX).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $14.20 and a one-year low of $5.21. Currently, BioCryst has an average volume of 2.76M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst (BCRX) Company Description:
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst price target raised to $11 from $10 at BofA
- BioCryst price target lowered to $20 from $25 at TD Cowen
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- BioCryst announces drug discovery updates ahead of R&D day
